834 related articles for article (PubMed ID: 33728999)
41. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
[No Abstract] [Full Text] [Related]
42. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
43. [Radiation therapy in thyroid cancer].
Sun XS; Guevara N; Fakhry N; Sun SR; Marcy PY; Santini J; Bosset JF; Thariat J
Cancer Radiother; 2013 Jun; 17(3):233-43; quiz 255-6, 258. PubMed ID: 23763764
[TBL] [Abstract][Full Text] [Related]
44. Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.
Zhou M; Chen Y; Adachi M; Wen X; Erwin B; Mawlawi O; Lai SY; Li C
Biomaterials; 2015 Jul; 57():41-9. PubMed ID: 25913249
[TBL] [Abstract][Full Text] [Related]
45. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
46. Optimal combination of treatment modality to increase survival in patients with anaplastic thyroid carcinoma: A STROBE compliant retrospective study.
Lee JH; Ahn HK; Seok JY; Lee KC; Chun YS; Chung YS; Lee YD
Medicine (Baltimore); 2018 Jun; 97(25):e11037. PubMed ID: 29923991
[TBL] [Abstract][Full Text] [Related]
47. Anaplastic thyroid carcinoma: a 25-year single-institution experience.
Mohebati A; Dilorenzo M; Palmer F; Patel SG; Pfister D; Lee N; Tuttle RM; Shaha AR; Shah JP; Ganly I
Ann Surg Oncol; 2014 May; 21(5):1665-70. PubMed ID: 24554064
[TBL] [Abstract][Full Text] [Related]
48. A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer.
Lee NY; Riaz N; Wu V; Brinkman T; Tsai CJ; Zhi W; Fetten J; Ho A; Wong RJ; Ghossein R; Tuttle M; Fagin J; Pfister DG; Sherman E
Thyroid; 2022 Jul; 32(7):799-806. PubMed ID: 35521657
[No Abstract] [Full Text] [Related]
49. Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer: A Single-Institution 21-Year Experience.
Wu SS; Lamarre ED; Yalamanchali A; Brauer PR; Hong H; Reddy CA; Yilmaz E; Woody N; Ku JA; Prendes B; Burkey B; Nasr C; Skugor M; Heiden K; Chute DJ; Knauf JA; Campbell SR; Koyfman SA; Geiger JL; Scharpf J
JAMA Otolaryngol Head Neck Surg; 2023 Apr; 149(4):300-309. PubMed ID: 36757708
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.
Sugitani I; Miyauchi A; Sugino K; Okamoto T; Yoshida A; Suzuki S
World J Surg; 2012 Jun; 36(6):1247-54. PubMed ID: 22311136
[TBL] [Abstract][Full Text] [Related]
51. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches.
Are C; Shaha AR
Ann Surg Oncol; 2006 Apr; 13(4):453-64. PubMed ID: 16474910
[TBL] [Abstract][Full Text] [Related]
52. The value of multimodal treatment in anaplastic thyroid cancer patients with distant metastasis.
Guo H; Lin H
BMC Surg; 2024 Mar; 24(1):79. PubMed ID: 38438944
[TBL] [Abstract][Full Text] [Related]
53. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
[No Abstract] [Full Text] [Related]
54. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
Califano I; Smulever A; Jerkovich F; Pitoia F
Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
[TBL] [Abstract][Full Text] [Related]
55. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines.
Silver Karcioglu A; Iwata AJ; Pusztaszeri M; Abdelhamid Ahmed AH; Randolph GW
Cancer Cytopathol; 2022 Mar; 130(3):174-180. PubMed ID: 34618407
[No Abstract] [Full Text] [Related]
56. Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer.
Kim HK; Kim SA; Jung EK; Lee KH; Lee JK; Kang HC; Joo YE; Lim SC; Yoon TM
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649820
[TBL] [Abstract][Full Text] [Related]
57. Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
Abe I; Lam AK
Curr Oncol Rep; 2021 Feb; 23(3):31. PubMed ID: 33582932
[TBL] [Abstract][Full Text] [Related]
58. Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.
Jannin A; Giudici F; de la Fouchardière C; Al Ghuzlan A; Wassermann J; Chougnet CN; Drui D; Godbert Y; Ilouz F; Bardet S; Zanetta S; Roudaut N; Batisse Lignier M; Groussin L; Klein M; Zerdoud S; Lamartina L; Baudin E; Decaussin-Petrucci M; Leteurtre E; Borson Chazot F; Do Cao C; Borget I; Hadoux J;
Thyroid; 2023 Oct; 33(10):1190-1200. PubMed ID: 37855745
[No Abstract] [Full Text] [Related]
59. Evaluation of anaplastic thyroid carcinoma in the Kurdistan region of Iraq.
Mustafa DH; Ahmed BS; Haweizy RM; Dewana AM
BMC Surg; 2022 Oct; 22(1):364. PubMed ID: 36271386
[TBL] [Abstract][Full Text] [Related]
60. Multimodality treatment of anaplastic thyroid cancer with nearly resolved effect.
Tseng YT; Chang TC
J Formos Med Assoc; 2015 Sep; 114(9):897-8. PubMed ID: 24755268
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
